ADVERTISEMENT
Antibiotics Aren’t Profitable Enough for Big Pharma to Make More
Health experts are calling to reward firms for bringing drugs that are effective against resistant strains to the market.
06 May 2019, 04:30 PM IST
(Bloomberg Businessweek) -- Achaogen Inc. spent 15 years racing to develop antibiotics against resistant superbugs. It targeted one of the most-feared superbugs lurking in intensive care units: carbapenem-resistant Enterobacteriaceae, or CRE, a strain that can kill up to half the people it attacks. Last June its first drug, Zemdri, which kills CRE bacteria in the test tube, was approved by U.S. regulators. From a public health perspe...
I’m already a Subscriber Sign In
To continue reading this story
Subscribe to unlock & enjoy all Members-only benefits
Choose a plan
Renews automatically. Cancel anytime.
As a Subscriber you get
Full Access to
NDTV Profit App
Exclusives
Premium Stories
Access to
Stories
Curated
Newsletters
20,000+
Research Reports
Priority Pass
to Special Events
Ad-Free
Experience
Members-Only
Rewards
Still Not convinced ? Know More
Get live Stock market updates, Business news, Today’s latest news, Trending stories, and Videos on NDTV Profit.
ADVERTISEMENT